Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhDNase I eye drops in ocular Graft-vs.-Host disease
NCT02702518Phase 2Terminated
- Sponsor
- University of Illinois Chicago
- Start
- Apr 2016
- Primary completion
- Apr 2020
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dornase alfa in ocular graft-versus-host disease (oGVHD) and dry eye syndrome (DED), sponsored by University of Illinois Chicago. Primary endpoint: Change in Corneal Surface Staining at 8 weeks. Started Apr 2016; status: terminated.
02
Drugs
dornase alfa
03
Conditions
ocular graft-versus-host disease (oGVHD)dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT02702518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02702518.